Naslov
Is denosumab a long-term option for the treatment of parathyroid carcinoma?

Autori
Baretić, Maja

Izvornik
Qjm-an international journal of medicine (1460-2725) 198 (2016), 4; 288-288

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pismo uredniku, znanstveni

Ključne riječi
denosumab ; karcinom paratiroidne žlijezde ; liječenje
(denosumab ; parathyroid carcinoma ; therapy)

Sažetak
During a 10 year period, eight patients with parathyroid carcinoma were followed at the University Hospital Center Zagreb, two younger female patients (age at diagnosis 31 and 32 years) had unfavorable course of disease. Aside from asymptomatic osteoporosis, they had no chronic consequences related to hypercalcemia and hyperparathyroidism. Each of the female patients underwent five extensive surgical procedures. Calcium as a tumor marker indicates the persistence of invisible disseminated metastases. They were treated intermittently with intravenous bisphosphonates (pamindronate or zoledronic acid), although their effect was decreased next therapeutic step was administration of cinacalcet. One of the patents received adjuvant neck radiation therapy, and the other will receive radiation therapy in the near future. Both patients had positive somatostatin receptor scintigraphy performed with Tc99 m Tektrotyd. As a consequence, they received a monthly administration of a long-acting somatostatin analog. Finally, denosumab was introduced in therapy. The application of denosumab was adjusted according to the current serum calcium level. A similar situation occurred with bisphosphonates ; the effect of denosumab vanished, and it was therefore administered in shorter time intervals. This begs the question of whether the tachyphylaxis was due to RANKL/ RANK receptor downregulation or was simply a consequence of tumor growth.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA